These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11023 related articles for article (PubMed ID: 15603188)

  • 41. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
    Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
    Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant DNA virus vectors for vaccination.
    Moss B
    Semin Immunol; 1990 Sep; 2(5):317-27. PubMed ID: 2134016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virus-like particles: a new family of delivery systems.
    Boisgérault F; Morón G; Leclerc C
    Expert Rev Vaccines; 2002 Jun; 1(1):101-9. PubMed ID: 12908517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mimotope vaccines for cancer immunotherapy.
    Sharav T; Wiesmüller KH; Walden P
    Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
    Ghose A; Iakhnina E; Spaner D; Tartaglia J; Berinstein NL
    Hum Gene Ther; 2000 Jun; 11(9):1289-301. PubMed ID: 10890739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
    Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
    Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry.
    Skinner MA; Laidlaw SM; Eldaghayes I; Kaiser P; Cottingham MG
    Expert Rev Vaccines; 2005 Feb; 4(1):63-76. PubMed ID: 15757474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors.
    Hussain SF; Paterson Y
    Cancer Immunol Immunother; 2005 Jun; 54(6):577-86. PubMed ID: 15650885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
    Anderson RJ; Schneider J
    Vaccine; 2007 Sep; 25 Suppl 2():B24-34. PubMed ID: 17698262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant viruses as a tool for therapeutic vaccination against human cancers.
    Bonnet MC; Tartaglia J; Verdier F; Kourilsky P; Lindberg A; Klein M; Moingeon P
    Immunol Lett; 2000 Sep; 74(1):11-25. PubMed ID: 10996623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
    Ertl HC
    Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Recombinant Canarypox Viruses Expressing Immunogens.
    Garanzini D; Del Médico-Zajac MP; Calamante G
    Methods Mol Biol; 2017; 1581():15-28. PubMed ID: 28374241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
    He Y; Munn D; Falo LD
    Expert Rev Vaccines; 2007 Dec; 6(6):913-24. PubMed ID: 18377355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Listeria as a vaccine vector.
    Bruhn KW; Craft N; Miller JF
    Microbes Infect; 2007 Aug; 9(10):1226-35. PubMed ID: 17719258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Poxvirus-based vectors as vaccine candidates.
    Pincus S; Tartaglia J; Paoletti E
    Biologicals; 1995 Jun; 23(2):159-64. PubMed ID: 7546658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant viral vaccines for cancer.
    Cawood R; Hills T; Wong SL; Alamoudi AA; Beadle S; Fisher KD; Seymour LW
    Trends Mol Med; 2012 Sep; 18(9):564-74. PubMed ID: 22917663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.
    DeLeo AB; Whiteside TL
    Expert Rev Vaccines; 2008 Sep; 7(7):1031-40. PubMed ID: 18767952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 552.